A Multi-PTM omics atlas uncovers novel aging regulators in colorectal cancer

Yujie Zhang1, Wei Zhang2,3, Tianyuan Li1

  • 1School of Medicine, Anhui University of Science & Technology, Huainan, 232001, China.

BMC Cancer
|December 11, 2025
PubMed
Abstract

Insights

Aging significantly impacts colorectal cancer (CRC) progression. This study reveals widespread post-translational modification (PTM) changes in aging CRC, identifying key proteins and pathways for future therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Aging Research

Background:

  • Aging is a major factor in colorectal cancer (CRC) development.
  • The role of post-translational modifications (PTMs) in aging-related CRC is not well understood.
  • The combined effects of phosphorylation, ubiquitination, and malonylation on aging pathways in CRC are unexplored.

Purpose of the Study:

  • To investigate the landscape of aging-related PTMs in colorectal cancer.
  • To characterize the coordinated influence of multiple PTMs on aging pathways in CRC.
  • To identify novel regulatory networks and potential therapeutic targets.

Main Methods:

  • Established a CRC-specific multiomics framework profiling phosphorylation, malonylation, and ubiquitination.
  • Analyzed differentially modified proteins using functional enrichment and protein-protein interaction (PPI) network analysis.
  • Integrated pathway databases (GO, KEGG) and literature evidence to reconstruct regulatory axes.

Main Results:

  • Identified extensive dysregulation of aging-related PTMs in CRC, including 162 ubiquitination, 64 phosphorylation, and 68 malonylation sites.
  • LMNB1 identified as a multi-PTM protein involved in nuclear structure control during senescence.
  • Highlighted CDK1, SOD2, and MAPK1 as potential PTM-regulated hub nodes in CRC aging.
  • Developed a signaling model showing PTM-mediated suppression of EGFR-RAS and activation of p38/p53 pathways in CRC aging.

Conclusions:

  • Presented the first integrative network map of aging regulation in CRC based on multiple PTMs.
  • Identified LMNB1 as a key regulatory target in the aging-CRC axis.
  • Provided a foundation for developing biomarkers and therapies targeting the aging-cancer axis in CRC.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K